BR0209662A - Method for the treatment and / or prophylaxis of conditions characterized by altered intestinal function and / or visceral pain in humans or non-human mammals. - Google Patents

Method for the treatment and / or prophylaxis of conditions characterized by altered intestinal function and / or visceral pain in humans or non-human mammals.

Info

Publication number
BR0209662A
BR0209662A BR0209662-5A BR0209662A BR0209662A BR 0209662 A BR0209662 A BR 0209662A BR 0209662 A BR0209662 A BR 0209662A BR 0209662 A BR0209662 A BR 0209662A
Authority
BR
Brazil
Prior art keywords
treatment
functional
prophylaxis
visceral pain
humans
Prior art date
Application number
BR0209662-5A
Other languages
Portuguese (pt)
Inventor
Douglas William Pierre Hay
Gareth John Sanger
Tadataka Yamada
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0112208A external-priority patent/GB0112208D0/en
Priority claimed from GB0129268A external-priority patent/GB0129268D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR0209662A publication Critical patent/BR0209662A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Abstract

"MéTODO PARA O TRATAMENTO E/OU PROFILAXIA DE CONDIçõES CARACTERIZADAS PELA FUNçãO ALTERADA DE INTESTINO E/OU DOR VISCERAL EM EM SERES HUMANOS OU MAMìFEROS NãO HUMANOS". Cujo método compreende a administração de uma quantidade eficaz, não tóxica e farmaceuticamente aceitável de um antagonista receptor de NK~ 3~, em que a condição caracterizada pela função alterada de intestino e/ou dor visceral é selecionada entre certas condições de síndrome de intestino irritável, distensão funcional abdominal, constipação funcional, diarréia funcional, outras condições de intestino e dor funcional abdominal."METHOD FOR TREATMENT AND / OR PROPHYLAXY OF CONDITIONS CHARACTERIZED BY CHANGE INTESTINATION AND / OR VISCINAL PAIN IN HUMAN OR NON HUMAN MUMMERS". Which method comprises administering an effective, non-toxic and pharmaceutically acceptable amount of an NK-3 -receptor antagonist, wherein the condition characterized by altered bowel function and / or visceral pain is selected from certain conditions of irritable bowel syndrome. , abdominal functional distension, functional constipation, functional diarrhea, other bowel conditions and abdominal functional pain.

BR0209662-5A 2001-05-18 2002-05-17 Method for the treatment and / or prophylaxis of conditions characterized by altered intestinal function and / or visceral pain in humans or non-human mammals. BR0209662A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0112208A GB0112208D0 (en) 2001-05-18 2001-05-18 New use
GB0129268A GB0129268D0 (en) 2001-12-06 2001-12-06 Novel use
PCT/US2002/015911 WO2002094187A2 (en) 2001-05-18 2002-05-17 Novel use

Publications (1)

Publication Number Publication Date
BR0209662A true BR0209662A (en) 2004-04-20

Family

ID=26246093

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209662-5A BR0209662A (en) 2001-05-18 2002-05-17 Method for the treatment and / or prophylaxis of conditions characterized by altered intestinal function and / or visceral pain in humans or non-human mammals.

Country Status (19)

Country Link
EP (1) EP1387687A4 (en)
JP (1) JP2004534761A (en)
KR (1) KR20040016865A (en)
CN (1) CN1269483C (en)
AR (1) AR045879A1 (en)
AU (1) AU2002303811B2 (en)
BR (1) BR0209662A (en)
CA (1) CA2447063A1 (en)
CZ (1) CZ20033115A3 (en)
HU (1) HUP0400966A2 (en)
IL (1) IL158701A0 (en)
MX (1) MXPA03010509A (en)
MY (1) MY134211A (en)
NO (1) NO20035121L (en)
NZ (1) NZ529462A (en)
PE (1) PE20021067A1 (en)
PL (1) PL367308A1 (en)
TW (1) TWI243678B (en)
WO (1) WO2002094187A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028678D1 (en) 2003-01-28 2010-09-23 Ironwood Pharmaceuticals Inc Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
PL1729734T3 (en) * 2004-03-30 2008-09-30 Smithkline Beecham Corp Spray dried pharmaceutical compositions
WO2005100997A2 (en) * 2004-04-16 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3)
JP2009510121A (en) * 2005-09-30 2009-03-12 スミスクライン・ビーチャム・コーポレイション Pharmaceutical composition
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
PL2384318T3 (en) 2008-12-31 2018-04-30 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR200452372Y1 (en) * 2010-05-14 2011-02-22 서일수 Communication line support device of construction lift
KR101034774B1 (en) * 2010-07-30 2011-05-17 (주)챔피온코리아 Lift device using the wire rope
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2887964B1 (en) 2012-08-21 2019-07-03 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
RS58969B1 (en) 2013-04-12 2019-08-30 Ardelyx Inc Nhe3-binding compounds and methods for inhibiting phosphate transport
CA2909752A1 (en) 2013-04-19 2014-10-23 Astrazeneca Ab A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP7292207B2 (en) 2017-01-09 2023-06-16 アルデリックス， インコーポレイテッド Compounds Useful for Treating Gastrointestinal Disorders
WO2018129557A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Inhibitors of nhe-mediated antiport

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719311B1 (en) * 1994-03-18 1998-06-26 Sanofi Sa Compounds that are selective antagonists of the human NK3 receptor and their use as drugs and diagnostic tools.
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
BR9809652A (en) * 1997-05-23 2001-09-11 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
TR200101412T2 (en) * 1998-11-20 2001-10-22 Smithkline Beecham S.P.A. New compounds.

Also Published As

Publication number Publication date
KR20040016865A (en) 2004-02-25
AR045879A1 (en) 2005-11-16
MY134211A (en) 2007-11-30
NZ529462A (en) 2005-07-29
WO2002094187A2 (en) 2002-11-28
AU2002303811B2 (en) 2005-07-07
NO20035121D0 (en) 2003-11-17
PL367308A1 (en) 2005-02-21
CZ20033115A3 (en) 2004-09-15
CA2447063A1 (en) 2002-11-28
IL158701A0 (en) 2004-05-12
EP1387687A2 (en) 2004-02-11
HUP0400966A2 (en) 2004-08-30
CN1509175A (en) 2004-06-30
PE20021067A1 (en) 2003-02-02
EP1387687A4 (en) 2006-07-05
TWI243678B (en) 2005-11-21
CN1269483C (en) 2006-08-16
NO20035121L (en) 2003-11-17
MXPA03010509A (en) 2004-03-02
JP2004534761A (en) 2004-11-18
WO2002094187A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
BR0209662A (en) Method for the treatment and / or prophylaxis of conditions characterized by altered intestinal function and / or visceral pain in humans or non-human mammals.
HK1033911A1 (en) Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodes
PT1225897E (en) COMPOSITION FOR THE TREATMENT OF OBSTIPACY AND IRRITAVEL INTESTINAL SYNDROME
UA89791C2 (en) Nutritional composition comprising indigestible oligosaccharides for the treatment and/or prevention of respiratory tract infection
EP0871735A4 (en) Therapeutic and diagnostic compositions
BRPI0314308B8 (en) opioid antagonists, their uses, and pharmaceutical composition
EP1549336A4 (en) Prevention and/or treatment of inflammatory bowel disease using pyy or agonists thereof
HK1102766A1 (en) 5ht2c receptor modulator compositions and methods of use 5ht2c
PT1041987E (en) PHARMACEUTICAL FORM OF ORAL DOSAGE, UNDERSTANDING A COMBINATION OF AN AGRONIST OF OPIOIDE AND NALTREXONE
IL151388A (en) Use of il-18 inhibitors
WO2001041748A3 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
CA2505964A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
BR0309095A (en) Use of osteoprotegerin for the treatment and / or prevention of fibrotic disease.
NZ334029A (en) Use of serotonin 5-HT1F agonist for the treatment of common colds or allergic rhinitis
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
BR0010669A (en) Method for treating fibrosis using an integrin alpha-4 subunit antagonist
BR9812131A (en) Compositions containing bergamotine to increase the oral bioavailability of pharmaceutical agents
TH78294B (en) The latest type of application
TH78294A (en) The latest type of application
RU2001105868A (en) APPLICATION OF KAYODA IMPLANTATION FOR PREVENTION OF UMBILICUS AND INGUINE-SCAVIC HERNIA IN PIGS
BR0206172A (en) Toilet splash protector

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.